Table 1 Clinical characteristics of the study participants
|  | BRONJ total cases (n = 38) | BRONJ cancer cases (n = 13) | BRONJ osteoporosis cases (n = 25) | Normal controls (n = 90) |
|---|---|---|---|---|
Age, years | 79.9 ± 11.7 | 60.1 ± 8.7 | 76.6 ± 8.8 | 41.1 ± 7.2 |
Males | 8 (21%) | 7 (53.8%) | 2 (8.0%) | 47 (52.2%) |
Diagnosed condition resulting in BP prescription |  |  |  | – |
 Cancer | 13 (34.2%) | 13 (100%) | 0 (0%) |  |
  Breast cancer | 6 (46.2%) | 6 (46.2%) | – |  |
  Multiple myeloma | 5 (38.5%) | 5 (38.5%) | – |  |
  Prostate cancer | 2 (15.4%) | 2 (15.4%) | – |  |
 Osteoporosis | 25 (65.7%) | – | 25 (100%) |  |
BP |  |  |  | – |
 Zoledronate | 11 (29.0%) | 8 (61.5%) | 3 (12.0%) |  |
 Alendronate | 10 (26.0%) | – | 10 (40.0%) |  |
 Residronate | 5 (13.2%) | – | 5 (20.0%) |  |
 Pamidronate | 3 (7.9%) | 3 (23.1%) | – |  |
 Ibandronate | 2 (5.3%) | – | 2 (8.0%) |  |
 Zoledronate/ibandronate | 1 (2.6%) | 1 (7.7%) | – |  |
 Unknown | 6 (15.8%) | 1 (7.7%) | 5 (20.0%) |  |
Duration of BP treatment before BRONJ occurrence, months | 42.7 ± 46.3 | 18.1 ± 13.9 | 56.0 ± 52.3 | – |